See other companies on Welcome to the Jungle
Valo Health
Platform for drug development and discovery
- 101-200 employees
- Healthcare
- B2B
- Enterprise
- Machine Learning
- SaaS
- Back Bay East, Boston, MA
Jump to section
Company mission
To make the drug discovery and development process faster, less expensive, and with a higher probability of success.
Our take
Drug development is a critical component of health care. Reducing costs, improving discovery processes, and accelerating drug development are all critical to success in the drug pipeline. Using human-centric data and ML-anchored computation, Valo Health’s integrated drug development platform, known as Opal, improves outcomes in drug development, by leveraging advanced data analysis.
Drug development entails a variety of steps including molecule discovery, clinical development, and target discovery. With the vast amount of data that is generated, a system like Opal incentivizes investment in outcomes that are more likely to correspond with effective treatments. This reduces the number and expense of clinical trials needed to demonstrate drug effectiveness.
There are a variety of competitors in the data-driven drug discovery field, including insitro, Atomwise, and Exscietia, but this vast market should still offer enough space for Valo Health to grow. In 2021, the company experienced a set-back in the surprise calling off of a merger that would have seen it go public, but despite this has continued to operate well and advance towards its goal of transforming the drug development process.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Pet Insurance
- 401K
- Fitness Reimbursement
- Flexible Time-off
- Commuter Reimbursement
- Medical, Dental, and Vision Insurance
- Corporate Engagement Opportunities with Local Non-Profit Organizations
Company values
- Put Patients First
- Succeed As A Team
- There Is No Failure
- Think The Best Of One Another
- Time Is Our Only Limitation
- Take Collective Ownership
Funding (last 2 of 7 rounds)
Nov 2021
$1m
LATE VC
Jul 2021
$33.5m
LATE VC
Total funding: $487.5m
Leadership
Brian Alexander
(CEO)Also a Partner at Flagship Pioneering. Previously SVP of Genentech, CEO of Foundation Medicine and was a n Associate Professor at Harvard Medical School.
Brett Blackman
(COO)Member of the Board of Directors at Stanley Manne Children's Research Institute. Previously Interim Chief Scientific Officer at Omega Therapeutics and was a Strategic R&D Advisor at Ohana Biosciences, Inc.
Articles
Jobs (5)
Software Engineering
Data
Other Engineering